Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11033552 DPP IV inhibitor formulations

Patent 11033552 was granted and assigned to Boehringer Ingelheim on June, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Boehringer Ingelheim

Current Assignee

Boehringer Ingelheim

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

June 15, 2021

Patent Application Number

16357357

Date Filed

March 19, 2019

Patent Citations

US Patent 10155000 Medical use of pharmaceutical combination or composition

US Patent 10023574 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

US Patent 10034877 Treatment for diabetes in patients inappropriate for metformin therapy

US Patent 10301313 Polymorphs

Patent Citations Received

US Patent 11919903 Polymorphs

0

US Patent 11911388 Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

0

US Patent 11911387 Vasoprotective and cardioprotective antidiabetic therapy

0

Patent Primary Examiner

Patent abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11033552 DPP IV inhibitor formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool